Skip to main content
SpringerLink
Log in

Vaccines

  • Chapter
  • First Online:
Pharmaceutical Biotechnology

  • 468 Accesses

Abstract

Vaccines are among the most successful health interventions against infectious diseases currently available. They prevent infectious diseases and are relatively cheap, making them very cost-effective.

The chapter starts with an introduction to vaccine immunology, discussing the function of the innate and adaptive immune system and the role of vaccine components (adjuvants and antigens) in activating them. An overview is given of the different arms of the adaptive immune response: humoral and cellular immunity and the concept of immunological memory.

Vaccines are a heterogeneous product group, ranging from classical live attenuated pathogens to fully synthetic peptides. The different vaccine concepts are discussed. Pros and cons of each concept are discussed, and representative examples are given. Platform technology based on viral vectors and mRNA, so successfully deployed during the COVID-19 pandemic, is also discussed.

The last part of the chapter is devoted to general aspects of vaccinology and vaccine development and manufacturing. This includes vaccine adjuvants, needle-free administration routes, vaccine production, and characterization.

After studying this chapter, the reader will have a basic understanding of vaccine immunology and knows the different types of vaccines, including mRNA and vector vaccines, how they work, how adjuvants work, and how vaccines are produced and controlled.

Sadly, Wim Jiskoot passed away by the time of publication of this sixth edition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahi YS, Bangari DS, Mittal SK (2011) Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11(4):307–320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Amorij JP, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slütter B, Bal SM, Bouwstra JA, Huckriede A, Jiskoot W (2012) Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release 161(2):363–376

    Article  CAS  PubMed  Google Scholar 

  • Batista FD, Harwood NE (2009) The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9(1):15–27

    Article  CAS  PubMed  Google Scholar 

  • Berings M, Karaaslan C, Altunbulakli C, Gevaert P, Akdis M, Bachert C, Akdis CA (2017) Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol 140(5):1250–1267

    Article  CAS  PubMed  Google Scholar 

  • Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nature Rev 18:498–513

    CAS  Google Scholar 

  • Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, MJ ME, Huang Y, Tomaras GD, Group HIVVTNS (2017) Immunogenicity of a novel clade B HIV-1 vaccine combination: results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS One 12(7):e0179597

    Article  PubMed  PubMed Central  Google Scholar 

  • CDC (2019). https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html. Accessed 24 Aug 2022

  • Chen X, Yang J, Wang L, Liu B (2020) Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics 10:6011–6023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Czerkinsky C, Holmgren J (2012) Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 354:1–18

    CAS  PubMed  Google Scholar 

  • Delves PJ, Roitt IM (2011) Roitt’s essential immunology, 12th edn. Wiley, Chichester

    Google Scholar 

  • Dolgin E (2021) The tangled history of mRNA vaccines. Nature 597:318–324

    Article  CAS  PubMed  Google Scholar 

  • Farmer E, Cheng MA, Hung C-F, Wu T-C (2021) Vaccination strategies for the control and treatment of HPV infection and HPV-associated cancer. Recent Results Cancer Res 217:157–195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Francis JN, Larche M (2005) Peptide-based vaccination: where do we stand? Curr Opin Allergy Clin Immunol 5(6):537–543

    Article  CAS  PubMed  Google Scholar 

  • Garcia L, Jidy MD, Garcia H, Rodriguez BL, Fernandez R, Ano G, Cedre B, Valmaseda T, Suzarte E, Ramirez M, Pino Y, Campos J, Menendez J, Valera R, Gonzalez D, Gonzalez I, Perez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Perez JL, Talavera A, Perez A, Marrero K, Ledon T, Fando R (2005) The vaccine candidate vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 73(5):3018–3024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Germanier R, Fuer E (1975) Isolation and characterization of gal E mutant ty 21a of salmonella typhi: a candi- date strain for a live, oral typhoid vaccine. J Infect Dis 131(5):553–558

    Article  CAS  PubMed  Google Scholar 

  • Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL (2019) Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J ImmunoTherapy Cancer 7:6. https://doi.org/10.1186/s40425-018-0495-7

    Article  CAS  Google Scholar 

  • Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5(7):505–517

    Article  CAS  PubMed  Google Scholar 

  • Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11(4 Suppl):S45–S53

    Article  CAS  PubMed  Google Scholar 

  • Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, Shea LD, Miller SD (2014) A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 8(3):2148–2160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jackson NAC, Kerster KE, Casimiro D, Gurunathan DRF (2020) The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5:11. https://doi.org/10.1038/s41541-020-0159-8

    Article  PubMed  PubMed Central  Google Scholar 

  • Ji N, Long M, Garcia-Vilanova A, Ault R, Moliva JI, Yusoof KA, Mukherjee N, Curiel TJ, Dixon H, Torrelles JB, Svatek RS (2022) Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer. Cancer Immunol Immunother 72(1):125–136. https://doi.org/10.1007/s00262-022-03236-y

    Article  CAS  PubMed  Google Scholar 

  • Kawai T, Akira S (2009) The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21(4):317–337

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kis EE, Winter G, Myschik J (2012) Devices for intradermal vaccination. Vaccine 30(3):523–538

    Article  CAS  PubMed  Google Scholar 

  • Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M et al (2022) SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial. J Infect Dis 225:1923–1932

    Article  CAS  PubMed  Google Scholar 

  • Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Öztürk Ö, Kranz LM, Berger H, Petschenka J, Diken M, Kreiter S, Yogev N, Waisman A, Karikó K, Türeci Ö, Sahin U (2021) A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371:145–153

    Article  CAS  PubMed  Google Scholar 

  • Kubler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mulbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A (2015) Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer 3:26

    Article  PubMed  PubMed Central  Google Scholar 

  • Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M (2017) PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev Vaccines 16(3):197–213

    Article  CAS  PubMed  Google Scholar 

  • Lighaam LC, Rispens T (2016) The immunobiology of immunoglobulin G4. Semin Liver Dis 3:200–215

    Article  Google Scholar 

  • Mallet E, Belohradsky BH, Lagos R, Gothefors L, Camier P, Carriere JP, Kanra G, Hoffenbach A, Langue J, Undreiner F, Roussel F, Reinert P, Flodmark CE, Stojanov S, Liese J, Levine MM, Munoz A, Schodel F, Hessel L, Hexavalent Vaccine Trial Study G (2004) A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 22(11–12):1343–1357

    Article  CAS  PubMed  Google Scholar 

  • Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8(5):351–360

    Article  CAS  PubMed  Google Scholar 

  • Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH (2015) Therapeutic cancer vaccines. J Clin Invest 125(9):3401–3412

    Article  PubMed  PubMed Central  Google Scholar 

  • Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5(12):905–916

    Article  CAS  PubMed  Google Scholar 

  • Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E (2020) Defining trained immunity and its role in health and disease. Nat Rev Immunol 20:375–388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Northrup L, Christopher MA, Sullivan BP, Berkland C (2016) Combining antigen and immunomodulators: emerging trends in antigen-specific immunotherapy for auto-immunity. Adv Drug Deliv Rev 98:86–98

    Article  CAS  PubMed  Google Scholar 

  • O’Hagan DT (1990) Intestinal translocation of particulates — implications for drug and antigen delivery. Adv Drug Deliv Rev 5(3):265–285

    Article  Google Scholar 

  • Oomen CJ, Hoogerhout P, Kuipers B, Vidarsson G, van Alphen L, Gros P (2005) Crystal structure of an anti- meningococcal subtype P1.4 PorA antibody pro- vides basis for peptide-vaccine design. J Mol Biol 351(5):1070–1080

    Article  CAS  PubMed  Google Scholar 

  • Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547(7662):217–221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Paradiso PR, Hogerman DA, Madore DV, Keyserling H, King J, Reisinger KS, Blatter MM, Rothstein E, Bernstein HH, Hackell J (1993) Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 92(6):827–832

    Article  CAS  PubMed  Google Scholar 

  • Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbe GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ (2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight 2(21):96381

    Article  PubMed  Google Scholar 

  • Pharmajet.com/regulatory-clearances (2022). Accessed 29 Aug 2022

    Google Scholar 

  • Pinschewer DD (2017) Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. Swiss Med Wkly 147:w14465

    PubMed  Google Scholar 

  • Pollock KMCHM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, McFarlane LR, O’Hara J, Lemm N, McKay P, Rampling T, YTM Y, Milinkovic A, Kingsley C, Cole T, Fagerbrink S, Aban M, Tanaka M, Mehdipour S, Robbins A, Budd W, Faust S, Hassanin H, Cosgrove CA, Winston A, Fidler S, Dunn D, McCormack S, Shattocka RJ, on behalf of the COVAC1 study Group (2022) Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine 44:101262

    Article  PubMed  PubMed Central  Google Scholar 

  • Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12(6):509–517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raz R, Koren R, Bass D (2001) Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in adults. Isr Med Assoc J 3(5):328–332

    CAS  PubMed  Google Scholar 

  • Roesch A, Zolls S, Stadler D, Helbig C, Wuchner K, Kersten G, Hawe A, Jiskoot W, Menzen T (2022) Particles in biopharmaceutical formulations, part 2: an update on analytical techniques and applications for therapeutic proteins, viruses, vaccines and cells. J Pharm Sci 111:933–950

    Article  CAS  PubMed  Google Scholar 

  • Rouphael NG, Lai L, Tandon S, McCullough MP, Kong Y, Kabbani S, Natrajan MS, Xu Y, Zhu Y, Wang D, O’Shea J, Sherman A, Yu T, Henry S, McAllister D, Stadlbauer D, Khurana S, Golding H, Krammer F, Mulligan MJ, Prausnitz MR (2021) Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial. NPJ Vaccines 6:89

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386(9988):31–45

    Article  Google Scholar 

  • Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, Kranz TM, Diken M, Kreiter S, Haas H, Attig S, Rae R, Cuk K, Kemmer-Brück A, Breitkreuz A, Tolliver C, Caspar J, Quinkhardt J, Hebich L, Stein M, Hohberger A, Vogler I, Liebig I, Renken S, Sikorski J, Leierer M, Müller V, Mitzel-Rink H, Miederer M, Huber C, Grabbe S, Utikal J, Pinter A, Kaufmann R, Hassel JC, Loquai C, Türeci Ö (2020) An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585:107–112

    Article  CAS  PubMed  Google Scholar 

  • Samuels S, Marijne Heeren A, Zijlmans H, Welters MJP, van den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, Schumacher TNM, van Beurden M, Jordanova ES, Haanen J, van der Burg SH, Kenter GG (2017) HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. Cancer Immunol Immunother 66(9):1163–1173

    Article  CAS  PubMed  Google Scholar 

  • Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D (2014) T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346(6205):98–101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sebastian M, Papachristofilou A, Weiss C, Fruh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A (2014) Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as con- solidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14:748

    Article  PubMed  PubMed Central  Google Scholar 

  • Shamji MH, Durham SR (2017) Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol 140(6):1485–1498

    Article  CAS  PubMed  Google Scholar 

  • Timmerman P, Puijk WC, Meloen RH (2007) Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J Mol Recognit 20(5):283–299

    Article  CAS  PubMed  Google Scholar 

  • van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16(4):219–233

    Article  PubMed  Google Scholar 

  • van der Maaden K, Jiskoot W, Bouwstra J (2012) Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 161(2):645–655

    Article  PubMed  Google Scholar 

  • van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Lowik MJ, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Melief CJ, Kenter GG, van der Burg SH (2013) HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 11:88

    Article  PubMed  PubMed Central  Google Scholar 

  • Vanlandschoot P, Roobrouck A, Van Houtte F, Leroux-Roels G (2002) Recombinant HBsAg, an apoptotic-like lipo-protein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocytes. Biochem Biophys Res Commun 297(3):486–491

    Article  CAS  PubMed  Google Scholar 

  • Vela Ramirez JE, Sharpe LA, Peppas NA (2017) Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev 114:116–131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Verbeke R, Lentacker I, De Smedt S, Dewitte H (2021) The dawn of mRNA vaccines: the COVID-19 case. J Control Release 333:511–520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vreden SG, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen JH (1991) Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg 45(5):533–538

    Article  CAS  PubMed  Google Scholar 

  • Waltz E (2022) China and India approve nasal Civid vaccines. Nature 609:450

    Article  CAS  PubMed  Google Scholar 

  • Wong G, Mendoza EJ, Plummer FA, Gao GF, Kobinger GP, Qiu X (2018) From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther 18(2):159–173

    Article  PubMed  Google Scholar 

Further Reading

  • Abbas AK, Lichtman AH, Pillai S (2019) Basic immunology: functions and disorders of the immune system, 6th edn. Elsevier/Saunders, Philadelphia

    Google Scholar 

  • Delves PJ, Martin SJ, Burton DR, Roitt IM (2017) Roitt’s essential immunology, 13th edn. Wiley, Hoboken

    Google Scholar 

  • Loffler P (2021) Review: Vaccine myth-buster — Cleaning up with prejudices and dangerous misinformation. Front Immunol 12:663280. https://doi.org/10.3389/fimmu.2021.663280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Orenstein WA, Offit PA, Edwards KM, Plotkin SA (2023) Plotkin’s vaccines, 8th edn. Elsevier, Cambridge

    Google Scholar 

  • Pollard AJ, Bijker EM (2021) A guide to vaccinology: from basic principles to new developments. Nat Reviews 22:83–100

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Biotherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands

    Wim Jiskoot, Gideon F. A. Kersten & Bram Slütter

  2. Coriolis Pharma, Martinsried, Germany

    Gideon F. A. Kersten

  3. Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands

    Enrico Mastrobattista

Authors
  1. Wim Jiskoot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gideon F. A. Kersten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Enrico Mastrobattista
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bram Slütter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gideon F. A. Kersten .

Editor information

Editors and Affiliations

  1. Utrecht University, Utrecht, The Netherlands

    Daan J. A. Crommelin

  2. Faculty of Pharmaceutical Sciences, The University of British Columbia (UBC), Vancouver, BC, Canada

    Robert D. Sindelar

  3. College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

    Bernd Meibohm

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jiskoot, W., Kersten, G.F.A., Mastrobattista, E., Slütter, B. (2024). Vaccines. In: Crommelin, D.J.A., Sindelar, R.D., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-031-30023-3_15

Download citation

Publish with us

Policies and ethics

Search

Navigation